George  Magrath net worth and biography

George Magrath Biography and Net Worth

Dr. Magrath, MD, currently serves as Chief Executive Officer and a Board member of Opus Genetics, which was recently acquired by Ocuphire Pharma during his tenure there as CEO. Dr. Magrath is a board-certified ophthalmologist with extensive clinical, business, and financial experience. Most recently, Dr. Magrath was CEO of Lexitas Pharma Services, a leading contract research organization in ophthalmology. Lexitas experienced a substantial growth in headcount, expanded into multiple additional service offerings, including an image reading center and a significant shift into retinal diseases, and was acquired by a top-tier private equity group during Dr. Magrath’s tenure. Prior to Lexitas, Dr. Magrath served as the medical director at Hovione, where the team he worked with was responsible for the development of proprietary assets in ophthalmology, dermatology, and respiratory. Dr. Magrath began his career as an equity analyst at Edison Investment Research where he covered small and mid-sized pharma and biotechnology companies. Dr. Magrath holds a Master of Applied Economics from Johns Hopkins University, a Master of Business Administration from The Citadel, and a Medical Degree from the Medical University of South Carolina.

What is George Magrath's net worth?

The estimated net worth of George Magrath is at least $8.88 million as of April 23rd, 2026. Magrath owns 1,741,344 shares of Opus Genetics stock worth more than $8,880,854 as of April 30th. This net worth approximation does not reflect any other investments that Magrath may own. Learn More about George Magrath's net worth.

How do I contact George Magrath?

The corporate mailing address for Magrath and other Opus Genetics executives is 37000 GRAND RIVER AVE. SUITE 120, FARMINGTON HILLS MI, 48335. Opus Genetics can also be reached via phone at 248-957-9024 and via email at [email protected]. Learn More on George Magrath's contact information.

Has George Magrath been buying or selling shares of Opus Genetics?

During the last quarter, George Magrath has sold $49,647.42 in Opus Genetics stock. Most recently, George Magrath sold 9,511 shares of the business's stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $5.22, for a transaction totalling $49,647.42. Following the completion of the sale, the chief executive officer now directly owns 1,741,344 shares of the company's stock, valued at $9,089,815.68. Learn More on George Magrath's trading history.

Who are Opus Genetics' active insiders?

Opus Genetics' insider roster includes Robert Gagnon (CFO), Cam Gallagher (Director), Cam Gallagher (Director), Ashwath Jayagopal (Insider), George Magrath (CEO), Joseph Schachle (COO), Benjamin Yerxa (President), and Benjamin Yerxa (President). Learn More on Opus Genetics' active insiders.

Are insiders buying or selling shares of Opus Genetics?

During the last year, Opus Genetics insiders bought shares 2 times. They purchased a total of 164,000 shares worth more than $323,890.00. During the last year, insiders at the sold shares 11 times. They sold a total of 4,073,395 shares worth more than $8,982,278.31. The most recent insider tranaction occured on April, 23rd when President Benjamin R Yerxa sold 7,470 shares worth more than $39,142.80. Insiders at Opus Genetics own 11.7% of the company. Learn More about insider trades at Opus Genetics.

Information on this page was last updated on 4/23/2026.

George Magrath Insider Trading History at Opus Genetics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/23/2026Sell9,511$5.22$49,647.421,741,344View SEC Filing Icon  
3/16/2026Sell24,438$5.21$127,321.981,750,855View SEC Filing Icon  
12/26/2024Buy100,000$0.98$98,000.00599,150View SEC Filing Icon  
11/18/2024Buy9,706$1.02$9,900.12492,950View SEC Filing Icon  
11/15/2024Buy90,294$1.01$91,196.94483,244View SEC Filing Icon  
See Full Table

George Magrath Buying and Selling Activity at Opus Genetics

This chart shows George Magrath's buying and selling at Opus Genetics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Opus Genetics Company Overview

Opus Genetics logo
Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.
Read More

Today's Range

Now: $5.11
Low: $4.70
High: $5.23

50 Day Range

MA: $4.74
Low: $3.39
High: $5.75

2 Week Range

Now: $5.11
Low: $0.90
High: $5.81

Volume

1,436,817 shs

Average Volume

905,997 shs

Market Capitalization

$364.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.52